Ozanimod for moderate Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether a daily pill called ozanimod can help people with moderate Alzheimer's disease. The study monitors changes in thinking and memory over time and requires a study partner who can join visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 55 and 80 years old.
- You must have a diagnosis of moderate Alzheimer's disease.
- You must be on stable doses of Alzheimer's medications for at least 3 months.
- You must have a study partner (family or friend) who spends at least 10 hours a week with you and can come to visits.
- You must not have other major health conditions like heart problems, recent stroke, or certain irregular heartbeats.
- You must not have had a live vaccine within 4 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a medicine called siponimod, already used for multiple sclerosis, can help people with mild Alzheimer's dementia. You will take a pill daily and be monitored closely for safety and cognitive changes.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.